SLC5A2 and diabetic kidney disease: Yet, the prevalence of DKD remains high despite intensive treatment with hyperglycemia control, blood pressure control, use of RAAS blockers [88] and the newer SGLT-2 inhibitors, GLP-1 receptor agonists and nsMRA therapies [89,90].